Detalles de la búsqueda
1.
Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry.
Ann Rheum Dis
; 2024 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38816065
2.
Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis.
Rheumatology (Oxford)
; 63(3): 594-607, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37725352
3.
Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis.
Ann Rheum Dis
; 82(12): 1538-1546, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37507201
4.
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Lancet
; 397(10271): 305-317, 2021 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33485455
5.
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study.
Ann Rheum Dis
; 2022 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35641124
6.
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
Ann Rheum Dis
; 81(3): 335-343, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34706874
7.
EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology.
Ann Rheum Dis
; 81(12): 1640-1646, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35210263
8.
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.
Ann Rheum Dis
; 81(5): 695-709, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34972811
9.
Human carbamylome description identifies carbamylated α2-macroglobulin and hemopexin as two novel autoantigens in early rheumatoid arthritis.
Rheumatology (Oxford)
; 61(7): 2826-2834, 2022 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34788409
10.
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.
Rheumatology (Oxford)
; 61(8): 3246-3256, 2022 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34897366
11.
Should we use glucocorticoids in early rheumatoid arthritis? Results at 5 years from the early RA UCLouvain Brussels cohort.
Rheumatology (Oxford)
; 60(12): 5576-5582, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33605405
12.
Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.
Rheumatology (Oxford)
; 60(12): 5583-5594, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33590829
13.
Glycosylation deficiency of lipopolysaccharide-binding protein and corticosteroid-binding globulin associated with activity and response to treatment for rheumatoid arthritis.
J Transl Med
; 18(1): 8, 2020 01 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31907043
14.
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools.
Clin Exp Rheumatol
; 38(6): 1056-1067, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33253107
15.
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
Ann Rheum Dis
; 78(11): 1454-1462, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31362993
16.
Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review.
Clin Exp Rheumatol
; 36(4): 658-667, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29600931
17.
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.
Ann Rheum Dis
; 75(1): 3-15, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25969430
18.
Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis.
Rheumatology (Oxford)
; 55(1): 49-55, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26268815
19.
Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.
Rheumatology (Oxford)
; 55(8): 1466-76, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27114562
20.
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.
Lancet
; 383(9914): 321-32, 2014 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-24168956